Iovance lifts 2026 revenue guidance to $410-420 million
The company points to strong U.S. uptake of Amtagvi and Proleukin, raising the midpoint by $55 million from its prior range.
SEC filing
Latest
5 stories
Tuesday, September 29
Thursday, August 6
Iovance posts record Q2 2026 revenue, gains FDA fast track for lifileucel in sarcomas
The company is reviewing its full-year revenue guidance after strong Amtagvi demand and reported progress across multiple registrational and next-generation TIL trials.
SEC filing